Effects of subanaesthetic dose of esketamine on pain and mood after laparoscopic bariatric surgery

A randomized controlled study exploring the practicability of subanesthetic doses of esketamine in improving pain and mood after laparoscopic bariatric surgery

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050874

Enrollment

Unknown

Registered

2021-09-05

Start date

2021-09-01

Completion date

Unknown

Last updated

2022-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain and mood disorders after laparoscopic bariatric surgery

Interventions

Esketamine group:Esselketamine 0.2mg/kg

Normal saline group:The same amount of normal saline

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years; 2. ASA I-II; 3. Patients undergoing laparoscopic gastric bypass or sleeve gastrectomy.

Exclusion criteria

Exclusion criteria: 1. History of cognitive impairment; 2. Previous misuse or abuse of ketamine; 3. Use of antipsychotic medications; 4. Stroke; 5. Head trauma, or intracranial mass or hemorrhage.

Design outcomes

Primary

Measure	Time frame
PHQ-9(Patien Health Questionnare) depression score;Visual analogue scale (VAS);QoR-15(quality of recovery);Serum brain-derived neurotrophic factor levels;Serum IL-6 levels;	—

Countries

China

Contacts

Public ContactWu Zhouquan

Changzhou Second People's Hospital

151897127@qq.com+86 13861023270

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026